A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Oesophagitis

Interventions

DRUG: Dupilumab
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]